高の原中央病院 DIニュース 年 月号

1 - 1 - 2016 4 2015 10 2 1 : 5-HT3 , 2 : 1 2 3 4 5 day 125 80 80 5-HT3 4mg/ , 1mg or ( ) ( ) ( ) ( ) , 8 8 8 (8) * 1 *5 * 4mg/ 1 : 5-HT3 , 2 : 1 2 3 4 5 day 5-HT3 4mg/ , 1mg or ( ) ( ) ( ) , ( ) 8 8 8 * 2 4 5-HT3 2 4 * 4mg/ CBDCA, IFM, CPT-11, MTX 1 : 5-HT3 , 2 : 1 2 3 4 5 day 125 80 80 5-HT3 4mg/ , 1mg or ( ) , ( ) 4 4 4 *2 * 4mg/ 1.

2 1 2 3 4 5 day , ( ) * * - 2 - high emetic risk ( 90%) ( 1,500 mg/m2) CPA CDDP DTIC moderate emetic risk ( 30 90%) IDR IFM CPT-11 BH-AC EPI l-OHP CBDCA ( 1,500 mg/m2) CPA ( 200 mg/m2) Ara-C DNR ADM, ADR THP-ADM BUS ( 250 mg/m2) MTX ( 50 mg/m2) L-PAM low emetic risk ( 10 30%) ETP GEM (100 200 mg/m2) Ara-C DTX PTX nab-PTX 5-FU 5-FU MIT (50 250 mg/m2) MTX MCNU minimal emetic risk ( 10%) L- L-ASP ( 100 mg/m2) Ara-C VNB VCR Flu BML ( 50 mg/m2)

3 MTX - 3 - 5-FU/CDDP 5-FU, CDDP high emetic risk S- 1/CDDP S- 1, CDDP ( 90%) FOLFOXIRI CPT-11, l-LV, l-OHP, 5-FU FOLFIRINOX l-OHP, l-LV, CPT-11, 5-FU, GEM/CDDP GEM, CDDP FOLFIRI l-LV, CPT-11, 5-FU IRIS S- 1, CPT-11 moderate emetic risk FOLFOX l-LV, l-OHP, 5-FU ( 30 90%) XELOX , , l-OHP SOX , S- 1, l-OHP GS GEM, S-1 GEM/nab-PTX GEM, nab-PTX CAP(CPM/ADR/CDDP) , CPM, ADR, CDDP TAP(PTX/ADR/CDDP) PTX, ADR, CDDP ( 90%) AP(ADR/CDDP) ADR, CDDP CPT-11/CDDP , CPT-11, CDDP TP(PTX/CDDP) PTX, CDDP TC(PTX/CBDCA) PTX, CBDCA ( 30 90%) DC(DTX/CBDCA) DTX, CBDCA MVAC MTX, VLB, ADR, CDDP ( 90%) GEM/CDDP GEM, CDDP ESHAP ETP, CDDP, Ara-C, mPSL ABVd ADR, BLM, VLB, DTIC CHOP CPA, ADR, VCR, PSL EPOCH ETP, CPA, ADR, VCR, PSL ( 90%) Hyper-CVAD/MA CPA, ADR, VCR, DEX, MTX, Ara-C DNR/Ara-C IDR/Ara-C ICE IFM, CBDCA, ETP DeVIC IFM, CBDCA, ETP, DEX C-MOPP CPA, VCR, PCZ, PSL VAD VCR, ADR, DEX, ( 30 90%) VCP VCR, CPA, PSL AC ADM, CPA EC EPI, CPA ( 90%) FAC 5-FU, ADM, CPA FEC 5-FU, EPI, CPA TAC DTX, ADM, CPA TC(DTX/CPA) DTX, CPA ( 30 90%) CMF CPA, MTX, 5 -FU 2015 10 2